Page 4 - Md Stanford University News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Conversations in the Cath Lab: Do You Use Antibiotics?
tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.
High-Deductible Insurance May Deter ED Visits for Chest Pain
tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.
May 27, 2021
Adding dapagliflozin to standard heart failure therapies provides “intermediate value” for American patients who have heart failure with reduced ejection fraction (HFrEF), a new cost-effectiveness analysis suggests at odds with earlier analyses that suggested the cost per quality-adjusted life-year (QALY) would be below the accepted $50,000 cutoff.
That’s because earlier studies, focused on settings outside the United States, considered both the “markedly lower” costs of the drug in countries like the United Kingdom, Germany, and Spain, as well as the lower overall healthcare costs in those nations, investigators led by Justin Parizo, MD (Stanford University, CA), say.
“Cost-effectiveness analyses are inherently tied to the society in which they’re evaluated,” senior author Alexander Sandhu, MD (Stanford University), explained to TCTMD. “While the clinical benefits might be quite similar across different contexts and populations, the costs of therapy
May 18, 2021
When omecamtiv mecarbil is used in patients who have chronic heart failure with reduced ejection fraction (HFrEF), the greater beneficial impact on clinical outcomes is seen in those with lower ejection fractions, a secondary analysis of the placebo-controlled GALACTIC-HF trial shows.
Among the prespecified subgroups in the trial, LVEF was the strongest modifier of the treatment effect, with larger reductions in the risk of HF events or CV death observed as values fell (
P = 0.004 for interaction). Reductions in NT-proBNP were greater at the lower end of the range, as well, John Teerlink, MD (San Francisco VA Medical Center and the University of California, San Francisco), reported during the recent virtual American College of Cardiology (ACC) 2021 Scientific Session.
December 14, 2020
In a world indelibly changed by COVID-19 more than 72 million confirmed cases and 1.6 million deaths, and counting people and institutions have proven adaptable and resilient: look no further than the development of vaccines and the rollout now underway.
That achievement would not have been possible without improvements and acceleration in the clinical research enterprise, something also seen within cardiology research, which had to respond quickly once it became clear that COVID-19 was affecting not just the lungs, but also the heart and other organs.
This story is part of
Envision Change, an end-of-2020 series imagining a different future for cardiology, medicine, research, and health. SEE ALSO: Funding the Future, Remaking Medicine, Heroes to Human.
vimarsana © 2020. All Rights Reserved.